
Annual report 2025
added 03-02-2026
Quanterix Corporation Retained Earnings 2011-2026 | QTRX
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Quanterix Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -577 M | -470 M | -434 M | -402 M | -305 M | -248 M | -216 M | -176 M | -144 M | -115 M | -88.6 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -88.6 M | -577 M | -289 M |
Quarterly Retained Earnings Quanterix Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -554 M | -521 M | -491 M | -470 M | - | -454 M | -445 M | -434 M | -414 M | -408 M | -402 M | -384 M | -349 M | -324 M | -305 M | -285 M | -270 M | -258 M | -248 M | -248 M | -248 M | -248 M | -216 M | -216 M | -216 M | -216 M | -176 M | -176 M | -176 M | -176 M | -144 M | -144 M | -144 M | -144 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -144 M | -554 M | -300 M |
Retained Earnings of other stocks in the Medical devices industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Align Technology
ALGN
|
2.48 B | $ 185.02 | -0.81 % | $ 13.9 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-533 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
-600 M | - | -26.83 % | $ 2.62 M | ||
|
Avinger
AVGR
|
-421 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
-374 M | - | - | $ 3.31 B | ||
|
AdaptHealth Corp.
AHCO
|
-633 M | $ 12.58 | -0.55 % | $ 1.7 B | ||
|
Allied Healthcare Products
AHPI
|
-15.7 M | - | 3.58 % | $ 2.21 M | ||
|
Aziyo Biologics
AZYO
|
-176 M | - | 1.37 % | $ 20.5 M | ||
|
Bruker Corporation
BRKR
|
2.41 B | $ 38.94 | -1.37 % | $ 5.8 K | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-185 M | - | -5.86 % | $ 30.6 M | ||
|
BioSig Technologies
BSGM
|
-718 M | - | 37.08 % | $ 85.7 M | ||
|
Conformis
CFMS
|
-581 M | - | - | $ 16.4 M | ||
|
EDAP TMS S.A.
EDAP
|
-82.6 M | $ 3.59 | 1.99 % | $ 134 M | ||
|
Boston Scientific Corporation
BSX
|
5.57 B | $ 63.42 | -1.83 % | $ 93.9 B | ||
|
Apollo Endosurgery
APEN
|
-337 M | - | - | $ 475 M | ||
|
Cardiovascular Systems
CSII
|
-424 M | - | 0.15 % | $ 844 M | ||
|
Cytosorbents Corporation
CTSO
|
-312 M | $ 0.61 | 3.18 % | $ 38 M | ||
|
ClearPoint Neuro
CLPT
|
-217 M | $ 10.5 | 0.38 % | $ 297 M | ||
|
Dynatronics Corporation
DYNT
|
-40.5 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
-514 M | - | - | $ 10.2 M | ||
|
Electromed
ELMD
|
21.2 M | $ 25.39 | -1.24 % | $ 215 M | ||
|
CryoLife, Inc.
CRY
|
20 M | - | -4.14 % | $ 702 M | ||
|
Second Sight Medical Products
EYES
|
-149 M | - | -0.97 % | $ 54.4 M | ||
|
Soliton, Inc.
SOLY
|
-70.6 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-56.2 M | - | -1.98 % | $ 98.3 M | ||
|
GBS
GBS
|
-62.5 M | - | -0.57 % | $ 7.12 M | ||
|
Itamar Medical Ltd.
ITMR
|
-119 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
-39.3 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-395 M | - | - | $ 111 M | ||
|
Globus Medical
GMED
|
1.39 B | $ 92.76 | -1.87 % | $ 12.5 B | ||
|
Helius Medical Technologies
HSDT
|
-160 M | $ 2.06 | 6.19 % | $ 1.25 M | ||
|
Butterfly Network
BFLY
|
-802 M | $ 5.29 | 8.74 % | $ 1.12 B | ||
|
Intersect ENT, Inc.
XENT
|
-303 M | - | - | $ 955 M | ||
|
Inogen
INGN
|
-176 M | $ 6.59 | 6.29 % | $ 175 M | ||
|
IRIDEX Corporation
IRIX
|
-92.4 M | $ 1.04 | - | $ 17.6 M | ||
|
OrthoPediatrics Corp.
KIDS
|
-275 M | $ 16.53 | -7.39 % | $ 388 M | ||
|
BIOLASE
BIOL
|
-317 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
-529 M | $ 10.83 | -1.46 % | $ 388 M | ||
|
Inspire Medical Systems
INSP
|
-146 M | $ 56.45 | -0.34 % | $ 1.66 B | ||
|
CONMED Corporation
CNMD
|
589 M | $ 37.91 | -3.88 % | $ 1.18 B | ||
|
LENSAR
LNSR
|
-178 M | $ 5.8 | -7.2 % | $ 69.4 M | ||
|
LivaNova PLC
LIVN
|
-1.15 B | $ 65.01 | -0.2 % | $ 3.55 B | ||
|
Integer Holdings Corporation
ITGR
|
994 M | $ 88.37 | 0.49 % | $ 3.07 B | ||
|
FONAR Corporation
FONR
|
-33.6 M | $ 18.76 | -0.05 % | $ 123 M | ||
|
Invacare Corporation
IVC
|
-78.4 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
14.2 B | $ 79.05 | 1.09 % | $ 46.2 B | ||
|
Penumbra
PEN
|
238 M | $ 331.47 | -0.29 % | $ 12.9 B | ||
|
Cutera
CUTR
|
-303 M | - | -10.19 % | $ 1.99 M |